New 10-Year Data on Arthrosamid® Safety Profile & 5-Year Data on Long Term Efficacy to Be Presented for the First Time at WCO 2025 (10-13 April)

So, as conference season begins, Contura is delighted to be presenting the latest and most compelling research evaluating both the long term safety and efficacy of intra-articular 2.5 % polyacrylamide hydrogel (iPAAG) at The 25^th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases WCO-IOF-ESCEO Congress taking place in Rome, Italy, from April 10-13, 2025.  

Professor Henning Bliddal will present two significant abstracts to delegates at the WCO, the world’s leading clinical conference on bone, joint and muscle health, providing further robust data which builds on the existing research portfolio of evidence for Arthrosamid® including:  

• Oral presentation: Friday 11^th October: 10-YEAR FOLLOW-UP AFTER INTRA-ARTICULAR INJECTIONS OF 2.5 % POLYACRYLAMIDE HYDROGEL FOR KNEE OSTEOARTHRITIS²  

Presenting authors: H. Bliddal.  Authors: A. Hartkopp, P. Conaghan & M. Henriksen 

Objective: To evaluate long term safety of intra-articular 2.5 % polyacrylamide hydrogel (iPAAG) 

Summary: Long-term results after iPAAG indicated a favourable safety profile of the product, with very few patients recalling pain or problems post-injection. Surgical records from subsequent knee replacements gave no indications of unusual adverse reactions.² 

• Poster abstracts:  P563 POLYACRYLAMIDE HYDROGEL FOR KNEE OSTEOARTHRITIS: 5-YEAR RESULTS FROM A PROSPECTIVE STUDY.³  

Authors: H. Bliddal J. Beier , A. Hartkopp , P. Conaghan, M. Henriksen 

Following on from the four-year data⁴ presented in September 2024 at the European Orthopaedic Research Society Meeting (EORS) in Aalborg, Denmark demonstrating the long-term efficacy of the hydrogel injection – this extended IDA Study shows that single injections of 6 ml intra-articular iPAAG were well tolerated and continued to provide clinically important effectiveness at 5-years after treatment.³ 

Details of both pieces of research are included in the WCO-IOF-ESCEO Congress Abstract Book.

Contura Orthopaedics Ltd is also proud to be the Welcome Cocktail Sponsor and looks forward to greeting guests during the opening evening of the congress from 19.10 -20.10 on Thursday 10^th April.  Anticipation will be high for the WCO Congress – with members of the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) developing an exciting scientific programme bringing together the world’s best in the field of musculoskeletal health and disease. 

The Contura team will be out in full force at the WCO, excited to network with and learn from colleagues from across the world, by attending symposia, abstract presentations and key discussions throughout the Congress. The team, including Mike Williams, Arthrosamid Global Brand Director, Bente Brünner, Medical Advisor & Arthrosamid Nordic Business Manager, Konstantin Lebediev, Head of Clinical and Medical Affairs, MD, MBA Contura International A/S, and Jeff Craven, Medical Affairs Manager Contura International A/S   will be based throughout the conference on Exhibition Stand 17.  

^References: 

^{1.Data on file} 

^{2. Bliddal, H.., et al. (2025) 10-Year Follow-Up After Intra-Articular Injections of 2.5% Polyacrylamide Hydrogel for Knee Osteoarthritis. Presented at WCO-IOF-ESCEO 2025.} 

^{3. Bliddal, H., et al. (2025) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 5 Years After Treatment. Presented at WCO-IOF-ESCEO 2025.}

^{4. Bliddal, H., et al. (2024) Polyacrylamide hydrogel for knee osteoarthritis: Four-year results from a prospective study. Orthop Procs. 2024;106-B(SUPP_18):106.} 

^{OUS/ARTHRO/APR2025/081}